Novel Nomenclature of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) for Future Hepatology

Abstract

Type 2 diabetes (T2D) has close relationships with nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and others. The European Hepatology Society International Hepatology Conference (EASL-ILC) 2023 presented the announcement of novel nomenclatures for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Furthermore, metabolic dysfunction-associated steatotic liver disease (MetALD) is used to describe those who consume greater amounts of alcohol, defined as more than 210g per week for males and more than 140g per week for females. MASLD may affect about one quarter of adults worldwide. Its criteria include the evidence of hepatic steatosis in three situations: obesity/overweight, T2DM, or the presence of metabolic dysfunction.